Roche Holding's latest study results show an experimental drug worked in a type of lung cancer for which new treatments are needed, Vontobel's Stefan Schneider says in a research note. The late-stage study tested Roche's divarasib drug candidate against other approved medications for a specific mutation of lung cancer and showed the product developed by the Swiss drugmaker led to meaningful improvements, the analyst says. "Efficacious treatments for this type of lung cancer represent a significant unmet need in lung cancer care," he adds. Vontobel estimates divarasib could generate 600 million Swiss francs in sales at its peak, and increases the probability that this forecast is hit to 80% from 40% previously. As a result, Vontobel lifts its target price on Roche stock to 348 francs from 346 francs. Roche shares closed at 328.80 francs Wednesday. (adria.calatayud@wsj.com)